Glenmark Speclt Drug Patent Portfolio
Glenmark Speclt owns 1 orange book drug protected by 15 US patents Given below is the list of Glenmark Speclt's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11679210 | Dispensing device and pharmaceutical composition for the treatment of rhinitis | 03 Sep, 2038 | Active |
| US10016443 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | 04 Sep, 2034 | Active |
| US10376526 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | 04 Sep, 2034 | Active |
| US10517880 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | 04 Sep, 2034 | Active |
| US10548907 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | 04 Sep, 2034 | Active |
| US10561672 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | 04 Sep, 2034 | Active |
| US10646500 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | 04 Sep, 2034 | Active |
| US10758550 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | 04 Sep, 2034 | Active |
| US10765686 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | 04 Sep, 2034 | Active |
| US11400101 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | 04 Sep, 2034 | Active |
| US12064442 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | 04 Sep, 2034 | Active |
| US9078923 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | 04 Sep, 2034 | Active |
| US9370483 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | 04 Sep, 2034 | Active |
| US9750754 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | 04 Sep, 2034 | Active |
| US9937189 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | 04 Sep, 2034 | Active |
Latest Legal Activities on Glenmark Speclt's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Glenmark Speclt.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Feb, 2024 | US10765686 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Feb, 2024 | US10758550 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Dec, 2023 | US9370483 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Oct, 2023 | US10646500 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 02 Aug, 2023 | US10561672 |
| Post Issue Communication - Certificate of Correction | 31 Jul, 2023 | US10016443 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Jul, 2023 | US10548907 |
|
Email Notification
Critical
| 29 Jun, 2023 | US10016443 |
|
Electronic Review
Critical
| 29 Jun, 2023 | US10016443 |
| Mail Pet Dec Routed to Certificate of Corrections Branch | 28 Jun, 2023 | US10016443 |
| Mail-Record a Petition Decision of Granted to Issue Patent in Name of the Assignee | 28 Jun, 2023 | US10016443 |
| Record a Petition Decision of Granted to Issue Patent in Name of the Assignee | 27 Jun, 2023 | US10016443 |
| Pet Dec Routed to Certificate of Corrections Branch | 27 Jun, 2023 | US10016443 |
|
Email Notification
Critical
| 23 Jun, 2023 | US10758550 |
|
Electronic Review
Critical
| 23 Jun, 2023 | US10758550 |
Glenmark Speclt's Family Patents
Glenmark Speclt drugs have patent protection in a total of 32 countries. It's US patent count contributes only to 20.8% of its total global patent coverage. Click
below to unlock the full patent family tree.
Glenmark Speclt Drug List
Given below is the complete list of Glenmark Speclt's drugs and the patents protecting them.
1. Ryaltris
Ryaltris is protected by 15 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11679210 | Dispensing device and pharmaceutical composition for the treatment of rhinitis |
03 Sep, 2038
(13 years from now)
| Active |
| US10016443 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
04 Sep, 2034
(9 years from now)
| Active |
| US10376526 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
04 Sep, 2034
(9 years from now)
| Active |
| US10517880 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
04 Sep, 2034
(9 years from now)
| Active |
| US10548907 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
04 Sep, 2034
(9 years from now)
| Active |
| US10561672 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
04 Sep, 2034
(9 years from now)
| Active |
| US10646500 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
04 Sep, 2034
(9 years from now)
| Active |
| US10758550 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
04 Sep, 2034
(9 years from now)
| Active |
| US10765686 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
04 Sep, 2034
(9 years from now)
| Active |
| US11400101 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
04 Sep, 2034
(9 years from now)
| Active |
| US12064442 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
04 Sep, 2034
(9 years from now)
| Active |
| US9078923 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
04 Sep, 2034
(9 years from now)
| Active |
| US9370483 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
04 Sep, 2034
(9 years from now)
| Active |
| US9750754 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
04 Sep, 2034
(9 years from now)
| Active |
| US9937189 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
04 Sep, 2034
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ryaltris's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List